Genomic biomarkers: Unveiling the potential for precise cancer therapy response.
作者信息
Kaur Gurjeet, Pahwa Paras, Prakash Ajay, Medhi Bikash
机构信息
Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2023 Jul-Aug;55(4):213-215. doi: 10.4103/ijp.ijp_442_23.
Abstract
摘要
相似文献
1
Genomic biomarkers: Unveiling the potential for precise cancer therapy response.基因组生物标志物：揭示精准癌症治疗反应的潜力。
Indian J Pharmacol. 2023 Jul-Aug;55(4):213-215. doi: 10.4103/ijp.ijp_442_23.
2
Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers.将癌症基因组学与治疗选择相结合：从基因组到预测性生物标志物。
Cancer. 2013 Nov 15;119(22):3914-28. doi: 10.1002/cncr.28304. Epub 2013 Aug 20.
3
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.实体瘤中癌症药物基因组生物标志物及临床可靶向性数据库。
Cancer Discov. 2015 Feb;5(2):118-23. doi: 10.1158/2159-8290.CD-14-1118.
4
The GENIE Is Out of the Bottle: Landmark Cancer Genomics Dataset Released.“基因魔瓶”被打开：具有里程碑意义的癌症基因组学数据集发布。
Cancer Discov. 2017 Aug;7(8):796-798. doi: 10.1158/2159-8290.CD-17-0604.
5
Translational genomics: the challenge of developing cancer biomarkers.转化基因组学：开发癌症生物标志物的挑战。
Genome Res. 2012 Feb;22(2):183-7. doi: 10.1101/gr.124347.111.
6
Genomically guided cancer treatments: from "promising" to "clinically useful".基因组引导的癌症治疗：从“有前景”到“临床可用”。
J Natl Cancer Inst. 2015 May 28;107(7). doi: 10.1093/jnci/djv168. Print 2015 Jul.
7
Genetics: genomic alteration profiles across different cancer types.遗传学：不同癌症类型的基因组改变图谱。
Nat Rev Clin Oncol. 2013 Dec;10(12):666. doi: 10.1038/nrclinonc.2013.185. Epub 2013 Oct 8.
8
AACR releases large cancer genomic data set from project GENIE.美国癌症研究协会发布了来自GENIE项目的大型癌症基因组数据集。
Cancer. 2017 May 15;123(10):1685. doi: 10.1002/cncr.30755.
9
Genomic profiling in oncology clinical practice.肿瘤临床实践中的基因组分析
Clin Transl Oncol. 2020 Sep;22(9):1430-1439. doi: 10.1007/s12094-020-02296-9. Epub 2020 Jan 24.
10
Transforming Biomarker Development with Exceptional Responders.利用特殊应答者推动生物标志物开发
Trends Cancer. 2018 Jan;4(1):3-6. doi: 10.1016/j.trecan.2017.11.004. Epub 2017 Dec 6.
引用本文的文献
1
Metabolic reprogramming and functional crosstalk within the tumor microenvironment (TME) and A Multi-omics anticancer approach.肿瘤微环境（TME）中的代谢重编程与功能串扰以及多组学抗癌方法。
Med Oncol. 2025 Jul 24;42(9):373. doi: 10.1007/s12032-025-02945-5.
2
Contemporary Update on Clinical and Experimental Prostate Cancer Biomarkers: A Multi-Omics-Focused Approach to Detection and Risk Stratification.前列腺癌临床与实验生物标志物的当代进展：一种聚焦多组学的检测与风险分层方法
Biology (Basel). 2024 Sep 25;13(10):762. doi: 10.3390/biology13100762.
本文引用的文献
1
Establishment and characterization of long-term human primary parathyroid tumor subclones derived from Indian PHPT.源自印度原发性甲状旁腺功能亢进症的长期人类原发性甲状旁腺肿瘤亚克隆的建立与表征
3 Biotech. 2023 May;13(5):161. doi: 10.1007/s13205-023-03540-z. Epub 2023 May 4.
2
Multilevel Annotation of Germline MEN1 Variants of Synonymous, Nonsynonymous, and Uncertain Significance in Indian Patients With Sporadic Primary Hyperparathyroidism.印度散发性甲状旁腺功能亢进症患者中胚系 MEN1 变异的同义、非同义及意义不明的多层次注释。
J Bone Miner Res. 2022 Oct;37(10):1860-1875. doi: 10.1002/jbmr.4653. Epub 2022 Aug 17.
3
Application of pharmacogenetics in oncology.药物遗传学在肿瘤学中的应用。
Biomark Res. 2020 Aug 17;8:32. doi: 10.1186/s40364-020-00213-4. eCollection 2020.
4
Oncotype DX Breast Recurrence Score: A Review of its Use in Early-Stage Breast Cancer.Oncotype DX 乳腺癌复发评分：在早期乳腺癌中的应用评价。
Mol Diagn Ther. 2020 Oct;24(5):621-632. doi: 10.1007/s40291-020-00482-7.
5
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing.利用全基因组测序技术对 2658 个人类癌症中的染色体重排进行全面分析。
Nat Genet. 2020 Mar;52(3):331-341. doi: 10.1038/s41588-019-0576-7. Epub 2020 Feb 5.
6
Pathogenic Germline Variants in 10,389 Adult Cancers.10389 例成年癌症中的致病变异体种系变异。
Cell. 2018 Apr 5;173(2):355-370.e14. doi: 10.1016/j.cell.2018.03.039.
7
New tools for old drugs: Functional genetic screens to optimize current chemotherapy.旧药新用的工具：功能遗传学筛选以优化现有化疗药物。
Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12.
8
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.表皮生长因子受体酪氨酸激酶抑制剂作为晚期表皮生长因子受体突变阳性非小细胞肺癌患者的一线治疗方案。
Oncotarget. 2017 Aug 9;8(43):75712-75726. doi: 10.18632/oncotarget.20095. eCollection 2017 Sep 26.
9
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.芦卡帕利维持治疗铂类化疗后缓解的复发性卵巢癌（ARIEL3）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12.
10
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.帕博利珠单抗作为晚期尿路上皮癌的二线治疗药物。
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.
Zotero 插件